Opinion

Video

Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

Related Videos
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Andrew Kuykendall, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Peter Forsyth, MD
Richard Kim, MD, Moffitt Cancer Center